BSE Live
Nov 04, 16:01Prev. Close
1158.05
Open Price
1156.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Nov 04, 15:57Prev. Close
1158.60
Open Price
1158.60
Bid Price (Qty.)
1149.10 (825)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 5,066.29 | 4,379.99 | 2,612.50 | 3,372.74 | 7,343.59 | |
| Net CashFlow From Operating Activities | 3,924.62 | 2,434.52 | 2,386.75 | 5,016.48 | 3,328.92 | |
| Net Cash Used In Investing Activities | -1,875.80 | -4,255.95 | -3,977.75 | -3,211.56 | 598.69 | |
| Net Cash Used From Financing Activities | 119.78 | 800.42 | 1,814.41 | -2,969.27 | -1,364.81 | |
| Foreign Exchange Gains / Losses | 9.10 | 14.17 | -0.06 | 0.20 | -2.12 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.66 | 0.00 | 6.41 | -3.25 | 22.41 | |
| Net Inc/Dec In Cash And Cash Equivalents | 2,178.36 | -1,006.84 | 229.76 | -1,167.40 | 2,583.09 | |
| Cash And Cash Equivalents Begin of Year | 3,385.43 | 4,392.27 | 4,162.51 | 5,329.91 | 2,746.82 | |
| Cash And Cash Equivalents End Of Year | 5,563.79 | 3,385.43 | 4,392.27 | 4,162.51 | 5,329.91 |
03.11.2025
09.10.2025
11.09.2025
Aurobindo Pharma shares rise 4.5% as report says GTCR strikes $4.8-bn deal to buy Zentiva
08.09.2025
Aurobindo Pharma shares fall on eight observations from USFDA
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
27.05.2025
Aurobindo Pharm Standalone March 2025 Net Sales at Rs 2,731.99 crore, down 5.6% Y-o-Y
12.02.2025
Aurobindo Pharm Standalone December 2024 Net Sales at Rs 2,916.63 crore, up 8.34% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL